medigraphic.com
ISSN 1029-3019 (Electronic)

2013, Number 09

<< Back Next >>

MediSan 2013; 17 (09)

Tocolytics in preterm delivery: a current dilemma

Nápoles MD

Language: Spanish
References: 41
Page: 5063-5079
PDF size: 318.91 Kb.


ABSTRACT

Preterm delivery is a worldwide major health problem with direct impact on perinatal morbidity and mortality, so currently tocolytic therapy has become a dilemma. In such a situation, the author of this article decided to review current literature on the subject in order to describe different drugs -- mechanisms of action, side effects, dosage, route of administration and time of use -- administered to inhibit preterm delivery, as well as new tocolytics under study, so that obstetricians have the information necessary to enable them to properly select the drug to be used individually and not in the population.


REFERENCES

  1. American College of Obstetricians and Gynecologists, Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin No. 127: Management of preterm labor. Obstet Gynecol. 2012; 119(6): 1308-17.

  2. Nápoles Méndez D. Consideraciones sobre el síndrome de respuesta inflamatoria fetal. MEDISAN. 2012 [citado 2 Jul 2013]; 16(11). Disponible en: http://bvs.sld.cu/revistas/san/vol_16_11_12/san151112.htm

  3. Benedetti TJ. Complicaciones graves del tratamiento betamimético para la inhibición pretérmino del parto. En: Clínicas de perinatología. 1986; 4: 815-25.

  4. Iams JD. Trabajo de parto pretérmino. En: Clínicas de Norteamérica 1988; 3: 505.

  5. Iams JD, Johnson F, Creasy RK. Prevención del parto pretérmino. En: Clínicas de Norteamérica. 1988; 3: 579-94.

  6. Cabero Roura L, Cabero Riera G. Tocolíticos en el manejo del parto prematuro. En: Parto prematuro. Madrid: Editorial Médica Panamericana; 2004. p. 145-58.

  7. Committee on Obstetric Practice. Use of progesterone to reduce preterm birth. ACOG Committee Opinion. 2008; 419.

  8. Caritis S, Darby M, Chan L. Tratamiento farmacológico del trabajo de parto pretérmino. En: Clínicas de Norteamérica. 1988; 3: 613-28.

  9. Carlin A, Norman J, Cole S, Smith R. Tocolytics and preterm labor. Obstet Anesth Digest. 2010; 30(1): 11.

  10. Alfirevic Z. Tocolytic: do they actually work? BMJ. 2012; 345: 6531.

  11. Fabry I, De Paepe P, Van Bortel L. Influence of tocolytics on central and peripheral hemodynamics. Basic Clin Pharmacol Toxicol. 2009; 105: 133-34.

  12. Kilpatrick S. Management of preterm labor. Obstet Gynecol. 2012; 119: 1308-17.

  13. Gaspar R, Hajagos-Toth J. Calcium channel blockers as tocolytics: Principles of their actions, adverse effects and therapeutic combinations. Pharmaceuticals. 2013; 6(6): 689-99.

  14. De Heus R, Mol BW, Erwich J-JHM, Van Geijn HP, Gyselaers WJ, Hanssens M, et al. Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. BMJ. 2009; 338: 744.

  15. Royal College of Obstetricians and Gynaecologists. Tocolysis for women in preterm labour. London: RCOG; 2011.

  16. Witter Fr, Zimmerman AW, Reichmann JP, Connors SL. In utero beta 2 adrenergic agonist exposure and adverse neurophysiologic and behavioral outcomes. Am J Obstet Gynecol. 2009; 201(6): 553-9.

  17. Langridge AT, Glasson EJ, Nassar N, Jacoby P, Pennell C, Hagan R, et al. Maternal conditions and perinatal characteristics associated with autism spectrum disorder and intellectual disability. PLOS One. 2013; 8(1): 50963.

  18. Moore T, Johnson S, Hennessy E, Marlow N. Screening for autism in extremely preterm infants: problems in interpretation. Dev Med Child Neurol. 2012; 54(6): 514-20.

  19. Bose DA, Assel B, Hill JB, Chauhan SP. Maintenance tocolytics for preterm symptomatic placenta previa: a review. Am J Perinatol. 2011; 28(1): 45-50.

  20. Carlin A, Norman J, Cole S, Smith R. Tocolytics and Preterm Labor. Obstetric Anesthesia Digest. 2010; 30(1): 11.

  21. Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2007; 196(5): 453-7.

  22. Van Geijin HP, Lenglet JE, Bolte AC. Nifedipine trials: effectiveness and safety aspects. BJOG. 2005; 112(1): 79-83.

  23. Nassar AH, Aoun J, Usta IM. Calcium channel blockers for the management of preterm birth: a review. Am J Perinatol. 2011; 28(1): 57-66.

  24. Coomarasamy A, Knox EM, Gee H, Song F, Khan KS. Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: a meta-analysis with an indirect comparison of randomized trials. BJOG. 2003; 110(12): 1045-9.

  25. Roos C, Spaanderman ME, Schuit E, Bloemenkamp KW, Bolte AC, Cornette J, et al. Effect of maintenance tocolysis with nifedipine in threatened preterm labor on perinatal outcomes: a randomized controlled trial. JAMA. 2013; 309(1): 41-7.

  26. Lyell DJ, Pullen KM, Mannan J, et al. Maintenance nifedipine tocolysis compared with placebo: a randomized controlled trial. Obstet Gynecol. 2008; 112(6): 1221-6.

  27. Abramovici A, Jenkins S. Network meta-analysis shows that prostaglandin inhibitors and nifedipine are best short-term tocolytics for preterm delivery. Evid Based Med. 2013. Feb 5.

  28. Singh N, Singh U, Seth S. Comparative study of nifedipine and isoxpurine as tocolytics for preterm labor. J Obstet Gynaecol India. 2011; 61(5): 512-5.

  29. Dodd JM, Crowther CA, Dare MR, Middleton P. Oral betamimetics for maintenance therapy after threatened preterm labour. Cochrane Database Syst Rev. 2006; (1): CD003927.

  30. Mackeen AD, Seibel-Seamon J, Grimes-Dennis J, Baxter J, Berghella V. Tocolytics for preterm premature rupture of membranes. Cochrane Database Syst Rev. 2011; (10): CD007062.

  31. Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ. 2012; 345: 6226.

  32. Carlin A, Norman J, Cole S, Smith R. Tocolytics and preterm labor. BMJ. 2009; 338: 195.

  33. Dodd JM, Flenady VJ, Cincotta R, Crowther C. Progesterone for the prevention of preterm birth: a systematic review. Obstet Gynecol. 2008; 112(1): 127-34.

  34. Tita AT, Rouse DJ. Progesterone for preterm birth prevention: an evolving intervention. Am J Obstet Gynecol. 2009; 200(3): 219-24.

  35. Da Fonseca ED, Bittar R, Damiao R, Zugaib M. Prematurity prevention: the role of progesterone. Curr Opin Obstet Gynecol. 2009; 21(2): 142-7.

  36. Aguilera M, Ramin K, Nguyen R, Giacobbe L, Swartout J. Emergency cerclage placement in multifetal pregnancies with a dilated cervix and exposed membranes: case series. AJP Rep. 2013; 3(1): 1–4.

  37. De Heus R, Mulder EJ, Derks JB, Visser GH. The effects of the tocolytics atosiban and nifedipine on fetal movements, heart rate and blood flow. J Matern Fetal Neonatal Med. 2009; 22(6): 485-90.

  38. Fox NS, Roman AS. Beta 2 adrenergic agents and autism. Am J Obstet Gynecol. 2010; 203(4):15.

  39. Kilburn KH, Thrasher JD, Immers NB. Do terbutaline- and mold-associated impairments of the brain and lung relate to autism? Toxicol Ind Health. 2009; 25(9- 10): 703-10.

  40. Akerlund M. Antioxitócicos como tocolíticos. En: Parto prematuro. Madrid: Editorial Médica Panamericana; 2004. p. 167-73.

  41. Tractocile® (atosiban). Ferring Pharmaceuticals. 2009 [citado 2 Jul 2013]. Disponible en:http://www.ferring.com.mx/custom/userfiles/file/html_files/Para_Medicos/Monogr afias_dipticos/Monografia_tractocile.swf




2020     |     www.medigraphic.com